Abstract:Whereas the mode of action of lamivudine (LAM) against hepatitis B virus (HBV) is well established, the inhibition mechanism(s) of interferon alpha (IFN-α) is less completely defined. To advance our understanding, we mathematically modeled HBV kinetics during 14-day pegylated IFN-α-2a (pegIFN), LAM, or pegIFN-plus-LAM (pegIFN+LAM) treatment of 39 chronically HBV-infected humanized uPA/SCID chimeric mice. Serum HBV DNA and intracellular HBV DNA were measured frequently. We developed a multicompartmental mathematical model and simultaneously fit it to the serum and intracellular HBV DNA data. Unexpectedly, even in the absence of an adaptive immune response, a biphasic decline in serum HBV DNA and intracellular HBV DNA was observed in response to all treatments. Kinetic analysis and modeling indicate that the first phase represents inhibition of intracellular HBV DNA synthesis and secretion, which was similar under all treatments with an overall mean efficacy of 98%. In contrast, there were distinct differences in HBV decline during the second phase, which was accounted for in the model by a time-dependent inhibition of intracellular HBV DNA synthesis, with the steepest decline observed during pegIFN+LAM treatment (1.28/day) and the slowest (0.1/day) during pegIFN monotherapy. Reminiscent of observations in patients treated with pegIFN and/or LAM, a biphasic HBV decline was observed in treated humanized mice in the absence of an adaptive immune response. Interestingly, combination treatment did not increase the initial inhibition of HBV production but rather enhanced second-phase decline, providing insight into the dynamics of HBV treatment response and the mode of action of IFN-α against HBV. IMPORTANCE Chronic hepatitis B virus (HBV) infection remains a global health care problem, as we lack sufficient curative treatment options. Elucidating the dynamics of HBV infection and treatment response at the molecular level could facilitate the development of novel, more effective HBV antivirals. Currently, the only well-established small animal HBV infection model available is the chimeric uPA/SCID mice with humanized livers; however, the HBV inhibition kinetics under pegylated IFN-α-2a (pegIFN) in this model system have not been determined in sufficient detail. In this study, viral kinetics in 39 humanized mice treated with pegIFN and/or lamivudine were monitored and analyzed using a mathematical modeling approach. We found that the main mode of action of IFN-α is blocking HBV DNA synthesis and that the majority of synthesized HBV DNA is secreted. Our study provides novel insights into HBV DNA dynamics within infected human hepatocytes.

Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver

Interferon stimulated immune profile changes in a humanized mouse model of HBV infection

Changes in the Cytokine Profiles of Patients with Chronic Hepatitis B during Antiviral Therapy

Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice

Switching from Entecavir to Pegifn Alfa-2a in Patients with Hbeag-Positive Chronic Hepatitis B: A Randomised Open-Label Trial (osst Trial)

TREATMENT WITH PEGYLATED INTERFERON-ALPHA INDUCES SUSTAINED SUPPRESSION OF BOTH VIRUS REPLICATION AND ANTIGENEMIA IN HUMANIZED Upa/scid MICE STABLY INFECTED WITH HBV

An HBV-tolerant immunocompetent model that effectively simulates chronic hepatitis B virus infection in mice.

Intrahepatic transcriptomics reveals gene signatures in chronic hepatitis B patients responded to interferon therapy

[Anti-Hbv Effect of Nucleotide Analogues on Mouse Model of Chronic HBV Infection Mediated by Recombinant Adeno-Associated Virus 8].

Antiviral therapy reduces hepatocellular carcinoma through suppressing hepatitis B virus replication may improve ER stress, mitochondrial and metabolic dysfunctions and decrease p62 in hybridized mice with single HBV transgene and miR‐122

Expression of Hepatitis B Virus Proteins in Transgenic Mice Alters Lipid Metabolism and Induces Oxidative Stress in the Liver.

Infection of Human Hepatocyte-chimeric Mice with HBV and in Vivo Treatment with Εrna

EFFICACY AND SAFETY OF PEGINTERFERON alfa-2a (40KD) IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS PARTICIPATING IN A RESPONSE-GUIDED THERAPY STUDY: AN INTERIM ANALYSIS AT WEEK 72

Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver

Transcriptomic and Proteomic Study of HBsAg Positive Transgenic Mouse Liver Suggests That Viral Protein Affects the Hepatocellular Metabolism of Sugar, Lipid and Amino Acids

Gene Expression Profiles in an Hepatitis B Virus Transfected Hepatoblastoma Cell Line and Differentially Regulated Gene Expression by Interferon-Alpha

Intrahepatic Exhausted Antiviral Immunity in an Immunocompetent Mouse Model of Chronic Hepatitis B

Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies

[Antiviral Effects of Dual-Target Antisense Rna: an Experimental Study with Hepatitis B Virus Transgenic Mice].

Entecavir Inhibits Hepatitis B Virus(hbv) Replication in HBV Replication Mice

Liver Chimeric Mice with Tupaia Hepatocyte Transplantation As an Animal Model for Hepatitis B Virus Infection and Antiviral Therapy